Crosas-Molist Eva, Fabregat Isabel
Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Spain.
Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Spain; Department of Physiological Sciences II, University of Barcelona, L'Hospitalet, Barcelona, Spain.
Redox Biol. 2015 Dec;6:106-111. doi: 10.1016/j.redox.2015.07.005. Epub 2015 Jul 14.
Liver fibrosis is the pathological consequence of chronic liver diseases, where an excessive deposition of extracellular matrix (ECM) proteins occurs, concomitantly with the processes of repair and regeneration. It is characterized by increased production of matrix proteins, in particular collagens, and decreased matrix remodelling. The principal source of ECM accumulation is myofibroblasts (MFB). Most fibrogenic MFB are endogenous to the liver, coming from hepatic stellate cells (HSC) and portal fibroblasts. Dysregulated inflammatory responses have been associated with most (if not all) hepatotoxic insults and chronic oxidative stress play a role during the initial liver inflammatory phase and its progression to fibrosis. Redox-regulated processes are responsible for activation of HSC to MFB, as well as maintenance of the MFB function. Increased oxidative stress also induces hepatocyte apoptosis, which contributes to increase the liver injury and to transdifferentiate HSC to MFB, favouring the fibrogenic process. Mitochondria and other redox-active enzymes can generate superoxide and hydrogen peroxide as a by-product in liver cells. Moreover, accumulating evidence indicates that NADPH oxidases (NOXs), which play a critical role in the inflammatory response, may contribute to reactive oxygen species (ROS) production during liver fibrosis, being important players in HSC activation and hepatocyte apoptosis. Based on the knowledge of the pathogenic role of ROS, different strategies to prevent or reverse the oxidative damage have been developed to be used as therapeutic tools in liver fibrosis. This review will update all these concepts, highlighting the relevance of redox biology in chronic fibrogenic liver pathologies.
肝纤维化是慢性肝病的病理结果,在此过程中细胞外基质(ECM)蛋白过度沉积,同时伴有修复和再生过程。其特征是基质蛋白,特别是胶原蛋白的产生增加,以及基质重塑减少。ECM积累的主要来源是肌成纤维细胞(MFB)。大多数致纤维化的MFB是肝脏内源性的,来自肝星状细胞(HSC)和门静脉成纤维细胞。炎症反应失调与大多数(如果不是全部)肝毒性损伤有关,慢性氧化应激在肝脏炎症初始阶段及其向纤维化进展过程中发挥作用。氧化还原调节过程负责将HSC激活为MFB,以及维持MFB功能。氧化应激增加还诱导肝细胞凋亡,这有助于加重肝损伤并使HSC转分化为MFB,促进纤维化过程。线粒体和其他氧化还原活性酶可在肝细胞中产生超氧化物和过氧化氢作为副产品。此外,越来越多证据表明,在炎症反应中起关键作用的NADPH氧化酶(NOXs)可能在肝纤维化过程中促进活性氧(ROS)的产生,是HSC激活和肝细胞凋亡的重要参与者。基于对ROS致病作用的认识,已开发出不同的策略来预防或逆转氧化损伤,用作肝纤维化的治疗工具。本综述将更新所有这些概念,强调氧化还原生物学在慢性纤维化肝脏疾病中的相关性。